Answers are grounded in this paper and cite their sources.
Introduction: Small cell lung carcinoma (SCLC) accounts for 15% of lung cancer cases. It is classified as extensive stage (ES-SCLC) when there is metastasis or if the volume of disease cannot be covered in a single radiotherapy field. Two-thirds of cases present with extensive disease and therefore with a poor prognosis. Despite achieving high objective response rates (ORR) to treatment, complete response (CR) rates do not exceed 3% and the vast majority of patients relapse early. Currently, immunotherapy, especially PD-1 axis blockade in combination with platinum-based chemotherapy is the standard of care. Clinical case: 57-year-old patient with stage ES-SCLC who achieved CR after four cycles of chemoimmunotherapy with durvalumab and carboplatin + etoposide, which is maintained after twenty-two months of treatment. Conclusion: A relationship has been found between ORR and survival, but it is unknown whether CR can be a surrogate for overall survival in SCLC in the era of immunotherapy. In this case, the absence of poor prognostic factors such as extra-thoracic metastatic disease probably favored CR. Biomarkers such as PD-L1 and TMB currently do not allow for treatment selection. In transcriptomic studies, the inflamed subtype (SCLC-I) appears to have a greater benefit from immunotherapy, however it requires prospective validation studies.
No takes yet. Share an insight, caveat, or question.
Charris et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: